Everything tirzepatide does, plus a third lever — glucagon — that raises metabolic rate. This is the next-gen weight-loss peptide, straight out of Phase 3. Research-grade, UK cold-chain, priced per vial.
Retatrutide is a triple agonist — GLP-1 + GIP + glucagon receptor (the TRAILBLAZER program, Eli Lilly). It's the 'next-gen' peptide: the same appetite suppression as the dual agents, plus a glucagon pathway that increases energy expenditure. Phase 3 is complete; 2026 approval watch.
Plain: everything tirzepatide does, plus a third lever — glucagon — which turns up your metabolic rate, so you burn more on top of the same appetite suppression. Technical: GLP-1R/GIPR/GCGR co-agonism; glucagon-receptor activation increases energy expenditure (thermogenesis) and modulates hepatic glucose output.
Obesity research (Phase 3 positive — roughly 24% mean body-weight loss at 48 weeks at 12 mg in TRAILBLAZER-1, per Phase 3 topline). The early-adopter pick for people who want the most aggressive next-gen option while supply is still niche.
Evidence: Evidence grade B — Phase 3 complete, approval pending as of 2026. The most advanced 'triple agonist' in the pipeline.
Typical research dosing: Typical: 4 mg weekly start, titrating to 8 / 12 mg (TRAILBLAZER arms). Our RT vials (5–15 mg × 10) support the full titration curve. (Typical research ranges.)
Side effects to know: GI (nausea, diarrhoea), a small increase in resting heart rate (the glucagon effect), rare gallstones. Class-typical GI profile.
Research-use product, supplied from GMP-grade sources. Not a licensed medicine and not for direct human consumption. Dosing shown = typical research/clinical ranges, not a prescription.
Pay by bank transfer and your whole order is 10% off. We give you a unique order number to quote as the reference, so we match your payment and dispatch without chasing you.
Daniel Brown · Sort code 23-69-72 · Account 34389126 · GBP (GB)
Use the Card button on any vial above — a secure Stripe link, choose how many vials at the gate, done in under a minute.
Every batch ships cold-chain with its Certificate of Analysis. Tracked, insured, UK-wide, next working day dispatch.
It adds a third pathway — glucagon — which raises metabolic rate/energy expenditure on top of the appetite suppression. In trials that's more weight loss at similar GI tolerability.
Phase 3 is complete; it's on the 2026 approval watch. That's why we supply it research-grade now — for researchers and early adopters ahead of launch.
GI effects similar to the rest of the class, plus a mild resting-heart-rate increase from the glucagon pathway. Typical for the class.
No — per-vial pricing, order one vial or a full course.